ArticleFrontiers in cellular and infection microbiology2025
Characteristics of metabolites analysis for patients with granulomatous lobular mastitis.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Local Triamcinolone Injection versus Anti-Tuberculosis Triple Therapy for Non-Puerperal Mastitis: A Comparative Study.International journal of women's health · 2026Article
- Development of a comprehensive dietary dataset for idiopathic granulomatous mastitis (IGM) patients and matched controls: protocol, implementation, and future directions for nutrition-based research.BMC research notes · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Granulomatous lobular mastitis (GLM) is a type of non-puerperal mastitis (NPM) associated with autoimmune factors. Previous studies suggest that gut microbiota dysbiosis may play a role in the pathological process of GLM; however, the specific role of gut microbiota metabolites in this process remains unclear. Therefore, this study aimed to investigate the gut metabolic characteristics of short-chain fatty acid (SCFA) in patients with GLM, a type of NPM. Methods: Stool samples were collected from 35 patients with GLM and 26 healthy control (HC) subjects. These samples underwent targeted metabolomic analysis to measure SCFA and 16s rRNA high-throughput sequencing to assess gut microbiota composition and differences between the groups. Results: Gas chromatography-mass spectrometry(GC-MS) analysis revealed that the content of SCFA-butanoic acid in the feces of patients with GLM was higher than that in the HC group. Notably, significant differences in metabolic pathways were observed between the HC and GLM groups. High-throughput sequencing results showed that the richness and diversity of gut microbiota in patients with GLM were significantly lower than those in healthy individuals. In addition, 53 bacterial species were found to differ significantly in abundance between the two groups. Moreover, the level of isohexanoic acid in the feces of patients with GLM with recurrence disease was significantly higher than that of patients without recurrence. Conclusions: Patients with GLM exhibit disturbances in gut butanoic acid metabolism and significant differences in gut microbiota structure compared to healthy individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.